Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|June 10, 2021

Ushering in the Golden Era of Alzheimer Drug Development?

Author(s)RJ Tesi, MD

What effect will aducanumab have on Alzheimer disease treatment?

RJ Tesi, MD, discusses the recent aducanumab FDA approval and the implications it will have on the treatment of Alzheimer disease.

Dr Tesi is CEO and Chief Medical Officer of INmuneBio.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

andranik123/Adobe Stock

Morning Rounds: August 17-23

ByJessica Walters

August 24th 2026

amyloid

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

August 24th 2026

Morning Rounds: News From August 10-16

ByJessica Walters

August 17th 2026

gguy/Adobe Stock

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

ByJessica Walters

August 14th 2026

Alzheimer

The State of Alzheimer Disease Care: An Update From Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

ByLeah Kuntz,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

August 3rd 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Migraine and Psychiatric Comorbidities

Skin and Psych: Using Habit Loop Science to Interrupt the Itch-Scratch Cycle, With Judson Brewer, MD, PhD

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Exploitation of Individuals With Psychosis